Zejula Added to UK’s Cancer Drugs Fund for Recurrent, Platinum-sensitive Ovarian Cancer

Zejula Added to UK’s Cancer Drugs Fund for Recurrent, Platinum-sensitive Ovarian Cancer
Women in England and Wales with recurrent, platinum-sensitive ovarian cancer can now access Zejula (niraparib) through the Cancer Drugs Fund (CDF) after a recommendation by the U.K.’s National Institute for Health and Care Excellence (NICE). Zejula, developed by Tesaro, is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance of ovarian cancer patients who are in a complete or partial response to platinum-based chemotherapy. Because this is the first PARP inhibitor shown to be effective in patients both with and without a BRCA mutation, NICE has recommended Zejula for women (regardless of BRCA mutation) who have received two lines of chemotherapy. “At Tesaro, we continue to globalize our mission and bring transformative therapies to patients. We are pleased that NICE will now provide more women with recurrent ovarian cancer in England and Wales access to Zejula through the CDF,” Orlando Oliveira, senior vice president and general manager of Tesaro, said in a press release. "Through close partnership with both NICE and NHS, Tesaro can now offer Zejula as an option for second-line maintenance treatment, regardless of a patient’s BRCA status," he added. The U.K.’s CDF is a source of funding for cancer drugs, providing patients earlier access to promising new treatments while
Subscribe or to access all post and page content.